Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Sufficiency of a Single Negative Thyroglobulin Standard for Judging the Success of Ablation in Low- and Intermediate-risk Differentiated Thyroid Cancer: A Retrospective Study

Author(s): Yahong Long, Jianhua Jin and Wanchun Zhang*

Volume 24, Issue 10, 2024

Published on: 08 January, 2024

Page: [1204 - 1214] Pages: 11

DOI: 10.2174/0118715303267441231128064729

Price: $65

Abstract

Background: We investigated how reduced successful ablation criteria may be used to evaluate radioiodine remnant ablation in patients with low- and intermediate-differentiated thyroid carcinoma (DTC).

Methods: Overall, 254 low- and intermediate-risk patients with DTC were categorized into three groups (positive, weak, positive, and negative) on the basis of a visual study of thyroid imaging performed before postoperative iodine treatment. Semi-quantitative analysis parameters were incorporated into the positive Tc-99m pertechnetate scanning to further examine the clinical use of thyroid imaging. We investigated the value of successful judgment criteria and the influencing factors of radioiodine ablation. At the same time, the predictive value of thyroglobulin (Tg) for radioiodine treatment and the overall clinical efficacy were assessed.

Results: A total of 250 (98.43%) patients were identified as having functional thyroid tissue residue on the Rx-whole-body scan, and 137 (53.94%) patients had positive Tc-99m pertechnetate scans using semi-quantitative analysis. The single Tg standard could not substitute the double standard (χ2c=22.042, p<0.001) for patients with residual thyroid weight by a semiquantitative analysis. However, the semi-quantitative analysis revealed no association between 99mTcO4−thyroid scan and ablation treatment using semi-quantitative analysis; only preablation sTg levels were related with success in the multivariate logistic regression analysis, with a cut-off value of 2.88 ng/mL. The pre-ablation stimulated Tg level was also the primary factor of satisfactory response following follow-up with an optimal cut-off of 6.506 ng/mL.

Conclusion: Even in low- and intermediate-risk patients with DTC, a single negative Tg standard also requires receiving some restrictions in the evaluation of ablation success and is inadequate. Conventional 99mTcO4 thyroid imaging combined with a quantitative analysis program can improve the clinical practice of single negative Tg standard.

« Previous Next »
Graphical Abstract

[1]
Chen, W.; Zheng, R.; Baade, P.D.; Zhang, S.; Zeng, H.; Bray, F.; Jemal, A.; Yu, X.Q.; He, J. Cancer statistics in China, 2015. CA Cancer J. Clin., 2016, 66(2), 115-132.
[http://dx.doi.org/10.3322/caac.21338] [PMID: 26808342]
[2]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin., 2018, 68(1), 7-30.
[http://dx.doi.org/10.3322/caac.21442] [PMID: 29313949]
[3]
Fagin, J.A.; Wells, S.A., Jr Biologic and clinical perspectives on thyroid cancer. N. Engl. J. Med., 2016, 375(11), 1054-1067.
[http://dx.doi.org/10.1056/NEJMra1501993] [PMID: 27959677]
[4]
Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.; Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; Schuff, K.G.; Sherman, S.I.; Sosa, J.A.; Steward, D.L.; Tuttle, R.M.; Wartofsky, L. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid, 2016, 26(1), 1-133.
[http://dx.doi.org/10.1089/thy.2015.0020] [PMID: 26462967]
[5]
Gao, Z.R.; Li, S.J. Guidelines for radioiodine therapy of differentiated thyroid cancer. Chin. J. Nucl. Mol. Imaging., 2021, 41, 218-241.
[http://dx.doi.org/10.3760/cma.j.cn.321828-20201113-00412]
[6]
Links, T.P.; van Tol, K.M.; Jager, P.L.; Plukker, J.T.; Piers, D.A.; Boezen, H.M.; Dullaart, R.P.; de Vries, E.G.; Sluiter, W.J. Life expectancy in differentiated thyroid cancer: A novel approach to survival analysis. Endocr. Relat. Cancer, 2005, 12(2), 273-280.
[http://dx.doi.org/10.1677/erc.1.00892] [PMID: 15947102]
[7]
Phan, H.T.T.; Jager, P.L.; Van der Wal, J.E.; Sluiter, W.J.; Plukker, J.T.M.; Dierckx, R.A.J.O.; Wolffenbuttel, B.H.R.; Links, T.P. The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur. J. Endocrinol., 2008, 158(1), 77-83.
[http://dx.doi.org/10.1530/EJE-07-0399] [PMID: 18166820]
[8]
Thies, E.D.; Tanase, K.; Maeder, U.; Luster, M.; Buck, A.K.; Hänscheid, H.; Reiners, C.; Verburg, F.A. The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging, 2014, 41(12), 2281-2290.
[http://dx.doi.org/10.1007/s00259-014-2851-2] [PMID: 25030619]
[9]
Shangguan, L.; Fang, S.; Zhang, P.; Han, S.; Shen, X.; Geng, Y.; Luo, D.; Zhao, C. Impact factors for the outcome of the first 131I radiotherapy in patients with papillary thyroid carcinoma after total thyroidectomy. Ann. Nucl. Med., 2019, 33(3), 177-183.
[http://dx.doi.org/10.1007/s12149-018-01321-w] [PMID: 30515649]
[10]
Giovanella, L.; Paone, G.; Ruberto, T.; Ceriani, L.; Trimboli, P. 99m Tc-pertechnetate scintigraphy predicts successful postoperative ablation in differentiated thyroid carcinoma patients treated with low radioiodine activities. Endocrinol. Metab., 2019, 34(1), 63-69.
[http://dx.doi.org/10.3803/EnM.2019.34.1.63] [PMID: 30784242]
[11]
Thientunyakit, T.; Pusuwan, P.; Tuchinda, P.; Khiewvan, B. The correlation of post-operative radioiodine uptake and Tc-99m pertechnetate thyroid scintigraphy and the result of thyroid remnant ablation. J. Med. Assoc. Thai., 2013, 96(9), 1199-1207.
[PMID: 24163997]
[12]
Zubair Hussain, S.; Zaman, M.; Malik, S.; Ram, N.; Asghar, A.; Rabbani, U.; Aftab, N.; Islam, N. Preablation stimulated thyroglobulin/TSH ratio as a predictor of successful I 131 remnant ablation in patients with differentiated thyroid cancer following total thyroidectomy. J. Thyroid Res., 2014, 2014, 1-7.
[http://dx.doi.org/10.1155/2014/610273] [PMID: 24987542]
[13]
Pan, M.; Li, Z.; Jia, M.; Lu, X. Combination of stimulated thyroglobulin and antithyroglobulin antibody predicts the efficacy and prognosis of 131I therapy in patients with differentiated thyroid cancer following total thyroidectomy: A retrospective study. Front. Endocrinol., 2022, 13, 857057.
[http://dx.doi.org/10.3389/fendo.2022.857057] [PMID: 35464061]
[14]
Piccardo, A.; Arecco, F.; Puntoni, M.; Foppiani, L.; Cabria, M.; Corvisieri, S.; Arlandini, A.; Altrinetti, V.; Bandelloni, R.; Orlandi, F. Focus on high-risk DTC patients: High postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival. Clin. Nucl. Med., 2013, 38(1), 18-24.
[http://dx.doi.org/10.1097/RLU.0b013e318266d4d8] [PMID: 23242039]
[15]
Kim, T.Y.; Kim, W.B.; Kim, E.S.; Ryu, J.S.; Yeo, J.S.; Kim, S.C.; Hong, S.J.; Shong, Y.K. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab., 2005, 90(3), 1440-1445.
[http://dx.doi.org/10.1210/jc.2004-1771] [PMID: 15613412]
[16]
Zhao, T.; Liang, J.; Guo, Z.; Li, T.; Lin, Y. In patients with low- to intermediate-risk thyroid cancer, a preablative thyrotropin level of 30 μIU/mL is not adequate to achieve better response to 131I therapy. Clin. Nucl. Med., 2016, 41(6), 454-458.
[http://dx.doi.org/10.1097/RLU.0000000000001167] [PMID: 26914559]
[17]
Fu, H.L.; Du, X.L.; Gu, Z.H.; Zou, R.J.; Wu, Z.; Wang, H. Analysis of influential factors for efficacy of 131I thyroid remnant ablation for differentiated thyroid carcinoma. J. Shanghai Jiaotong Univ., 2010, 30, 249-252.
[18]
Li, X.F. Clinical efficacy and risk factors of first 131I remnant ablation in atients with differentiated thyroid carcinoma after thyroidectomy; Paper, 2019.
[19]
Prpic, M.; Dabelic, N.; Stanicic, J.; Jukic, T.; Milosevic, M.; Kusic, Z. Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid: a comparison of ablation success with different activities of radioiodine (I-131). Ann. Nucl. Med., 2012, 26(9), 744-751.
[http://dx.doi.org/10.1007/s12149-012-0637-9] [PMID: 22829399]
[20]
Wang, C.; Diao, H.; Ren, P.; Wang, X.; Wang, Y.; Zhao, W. Efficacy and affecting factors of 131I thyroid remnant ablation after surgical treatment of differentiated thyroid carcinoma. Front. Oncol., 2018, 8, 640.
[http://dx.doi.org/10.3389/fonc.2018.00640] [PMID: 30619772]
[21]
Gao, W.; Liang, J.; Zhao, T.; Li, J.; Lin, Y.S. The impact of lymph node metastatic rate on clinical outcome following 131I therapy in patients with papillary thyroid carcinoma. China Oncology, 2016, 26(1), 67-72.
[22]
Yasmin, T.; Adnan, S.; Younis, M.N.; Fatima, A.; Shahid, A. Comparing high and low-dose radio-iodine therapy in thyroid remnant ablation among intermediate and low-risk papillary thyroid carcinoma patients-single centre experience. Dose Response, 2021, 19(4), 15593258211062775.
[http://dx.doi.org/10.1177/15593258211062775] [PMID: 34987336]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy